Clemizole - Eiger BioPharmaceuticals

Drug Profile

Clemizole - Eiger BioPharmaceuticals

Alternative Names: Clemizole hydrochloride

Latest Information Update: 06 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eiger BioPharmaceuticals
  • Developer Eiger BioPharmaceuticals; Eiger BioPharmaceuticals, Inc.
  • Class Antiallergics; Antiepileptic drugs; Antihistamines; Benzimidazoles; Small molecules
  • Mechanism of Action Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatocellular carcinoma
  • Discontinued Hepatitis C

Most Recent Events

  • 06 Mar 2017 Discontinued - Phase-I for Hepatitis C in Australia and New Zealand (PO)
  • 13 Feb 2017 Phase-II clinical trials in Hepatocellular carcinoma in Turkey (PO) (NCT03069508)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C in Australia (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top